Plasma Protein Patterns Associated with Paliperidone Palmitate Maintenance Therapy in Schizophrenia: A Prospective Cohort Study

作者：Weiwei Zeng, Feiqing Liang, Xiaoying Lin, Yaoyuan Zhang, Ya Zheng, Tahir Ali, Haibin Dai · 发表于：CNS Drugs · 年份：2025 · DOI：10.1007/s40263-025-01220-5 · 被引用次数：3 · 研究领域：Schizophrenia research and treatment、Tryptophan and brain disorders、Bipolar Disorder and Treatment

BACKGROUND AND OBJECTIVE: Patients with schizophrenia exhibit significant interindividual variations in their response to pharmacotherapy, adverse effects, and clinical outcomes. While once-monthly paliperidone palmitate (PP1M) injections can improve treatment adherence and continuity compared with oral formulations, suboptimal therapeutic outcomes are still observed in some patients. Although the mechanisms underlying the variability in efficacy of long-acting injectables (LAIs) remain unclear, studies suggest an association with alterations in plasma protein expression. This study aims to investigate the correlation between interindividual differences in the response to PP1M treatment and changes in plasma protein abundance using proteomic analysis. METHODS: This prospective cohort study was conducted in Longgang District, Shenzhen, China. Utilizing Olink Proximity Extension Assay (PEA) proteomics technology, we analyzed plasma samples from 27 healthy controls and 28 patients with schizophrenia who were clinically indicated for and initiated on maintenance therapy with once-monthly paliperidone palmitate long-acting injection (PP1M), as assessed by their treating physicians. Plasma abundance levels of 92 proteins were measured in all patients with schizophrenia, both prior to their first PP1M administration and following at least 3 months of PP1M treatment. RESULTS: Our findings demonstrated that maintenance therapy with PP1M for at least 3 months effectively sustained and ...